Precision for Medicine announced a strategic partnership with SOPHiA GENETICS to enhance its biomarker discovery and precision medicine services. As part of this collaboration, Precision for Medicine will integrate the SOPHiA DDM Platform for biomarker discovery, clinical trial assays (CTAs), and advanced algorithms to expand clinical trial capabilities. This partnership will further enhance service offerings and provide biopharma companies with tools to accelerate clinical trial design, patient stratification, and data analysis.
Through this partnership, Precision for Medicine will leverage the SOPHiA DDMTM Platform’s advanced AI-driven algorithms to analyze complex multimodal data, including genomic, radiomic, and clinical data. This capability will allow biopharma companies to identify and target the most appropriate patient populations for clinical trials, accelerating biomarker discovery and improve diagnostic capabilities. This is crucial for precision medicine efforts in oncology, rare diseases, and genetic disorders, where understanding the specific genomic characteristics of each patient may enable more targeted therapies.
Additionally, MSK-ACCESS®? powered with SOPHiADDMTM, an innovative liquid biopsy test being deployed globally with the support of AstraZeneca, will be made available as a Precision for Medicine service for biopharma clients. Data generated by this genomically rich, globally deployed test will enable retrospective clinical trial data analysis and improve patient stratification.
This capability allows biopharma companies to refine and optimize their clinical trial designs by better understanding how patients responded to previous treatments. This evidence-based approach can help companies fine-tune their drug development strategies, improve patient recruitment for trials, and gain deeper insights into the efficacy of therapies in real-world settings. Through this partnership, Precision For Medicine will provide wet lab services, alongside data analysis and clinical trial support, offering biopharma companies expanded capabilities under one umbrella.
This integrated approach allows clients to rely on a single solution provider, with Precision for Medicine and SOPHiA GENETics working together to deliver seamless end-to-end support for their drug development programs. Precision for Medicine’s established clinical trial expertise, including biomarker testing and wet lab services, combined with SOPHiA GENetICS’ AI-based genomic analysis tools, creates a powerful comprehensive solution for biopharma companies. Biopharma clients can now accelerate drug development with a seamless solution for data analysis and clinical support, enabling more efficient progression from preclinical research to market readiness. This collaboration provides a competitive edge, allowing clients to bring innovative therapies to patients faster and improve market positioning in the highly competitive biopharma landscape.
This exciting partnership is a key driver of innovation in precision medicine, providing biopharma companies with tools To better understand patient genomic makeup and develop personalized treatments for complex diseases. SOPHiA DDMT M Platform is a key driver of innovation In precision medicine, providing biopharm companies with tools to better understand patient genomic makeup and developed personalized treatments for complex diseases.
